Cargando…
髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征
OBJECTIVE: To analyze the clinical manifestations and laboratory features in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte (T-LGL) proliferation. METHODS: The clinical data of 5 patients with myeloid neoplasms complicated with clonal T-LGL proliferation from Nov...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364924/ https://www.ncbi.nlm.nih.gov/pubmed/32447929 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.04.003 |
_version_ | 1783559933998923776 |
---|---|
collection | PubMed |
description | OBJECTIVE: To analyze the clinical manifestations and laboratory features in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte (T-LGL) proliferation. METHODS: The clinical data of 5 patients with myeloid neoplasms complicated with clonal T-LGL proliferation from November 2017 to November 2018 in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were analyzed retrospectively. RESULTS: The median age was 60 years old. All patients had a history of abnormal peripheral blood cell counts for over 6 months. The absolute lymphocyte count in peripheral blood was less than 1.0×10(9)/L. In addition to the typical T-LGL phenotype, the immunophenotype was heterogenous including CD4(+)CD8(−) in 2 patients, the other 3 CD4(−)CD8(+). Four patients were αβ type T cells, the other one was γδ type. STAT3 mutation was detected in 1 patient by next-generation sequencing, the other 4 cases were negative. CONCLUSION: Clonal T-LGL proliferation with myeloid neoplasm develops in an indolent manner, mainly in elderly patients. Hemocytopenia is the most common manifestation. The diagnosis of T-LGL proliferation does not have specific criteria, that it should be differentiated from other T cell proliferative disorders, such as T-cell clones of undetermined significance. STAT3 or STAT5b mutation may help distinguish. |
format | Online Article Text |
id | pubmed-7364924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73649242020-07-16 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the clinical manifestations and laboratory features in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte (T-LGL) proliferation. METHODS: The clinical data of 5 patients with myeloid neoplasms complicated with clonal T-LGL proliferation from November 2017 to November 2018 in Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were analyzed retrospectively. RESULTS: The median age was 60 years old. All patients had a history of abnormal peripheral blood cell counts for over 6 months. The absolute lymphocyte count in peripheral blood was less than 1.0×10(9)/L. In addition to the typical T-LGL phenotype, the immunophenotype was heterogenous including CD4(+)CD8(−) in 2 patients, the other 3 CD4(−)CD8(+). Four patients were αβ type T cells, the other one was γδ type. STAT3 mutation was detected in 1 patient by next-generation sequencing, the other 4 cases were negative. CONCLUSION: Clonal T-LGL proliferation with myeloid neoplasm develops in an indolent manner, mainly in elderly patients. Hemocytopenia is the most common manifestation. The diagnosis of T-LGL proliferation does not have specific criteria, that it should be differentiated from other T cell proliferative disorders, such as T-cell clones of undetermined significance. STAT3 or STAT5b mutation may help distinguish. Editorial office of Chinese Journal of Hematology 2020-04 /pmc/articles/PMC7364924/ /pubmed/32447929 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.04.003 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title | 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title_full | 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title_fullStr | 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title_full_unstemmed | 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title_short | 髓系肿瘤合并克隆性T大颗粒淋巴细胞增殖的临床及实验室特征 |
title_sort | 髓系肿瘤合并克隆性t大颗粒淋巴细胞增殖的临床及实验室特征 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364924/ https://www.ncbi.nlm.nih.gov/pubmed/32447929 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.04.003 |
work_keys_str_mv | AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng AT suǐxìzhǒngliúhébìngkèlóngxìngtdàkēlìlínbāxìbāozēngzhídelínchuángjíshíyànshìtèzhēng |